De-Intensification of Antidiabetic Treatment Using Canagliflozin in Patients with Heart Failure and Type 2 Diabetes: Cana-Switch-HF Study

Canagliflozin is a sodium-glucose co-transporter 2 inhibitor that reduces glycemia as well as the risk of cardiovascular events. Our main objective was to analyze antidiabetic treatment de-intensification and the glycemic efficacy of replacing antidiabetic agents (excluding metformin) with canaglifl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Clin Med
Hauptverfasser: Pérez-Belmonte, Luis M., Ricci, Michele, Sanz-Cánovas, Jaime, Cobos-Palacios, Lidia, López-Carmona, María D., Ruiz-Moreno, M. Isabel, Millán-Gómez, Mercedes, Bernal-López, M. Rosa, Jansen-Chaparro, Sergio, Gómez-Huelgas, Ricardo
Format: Artigo
Sprache:Inglês
Veröffentlicht: MDPI 2021
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8125841/
https://ncbi.nlm.nih.gov/pubmed/34066707
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm10092013
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge